Sol-Gel Technologies Ltd.
SLGLDrugs in Pipeline
8
Phase 3 Programs
7
Upcoming Catalysts
2
Next Catalyst
This month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
Patidegib Topical Gel Phase 3 Est. Readout
Primary completion for Patidegib Topical Gel trial (NCT06050122) in Gorlin Syndrome
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
S6G5T-8
Acne Vulgaris
S6G5T-3
Acne Vulgaris
Patidegib Topical Gel, 2%
Basal Cell Nevus Syndrome
S5G4T-2
Papulopustular Rosacea
S5G4T-1
Papulopustular Rosacea
5-FU Cream
Actinic Keratosis (AK)
Patidegib Topical Gel
Gorlin Syndrome
DER 45 EV
Rosacea
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
S6G5T-8 | Phase 3 | Acne Vulgaris | - | - |
S6G5T-3 | Phase 3 | Acne Vulgaris | - | - |
Patidegib Topical Gel, 2% | Phase 3 | Basal Cell Nevus Syndrome | - | - |
S5G4T-2 | Phase 3 | Papulopustular Rosacea | - | - |
S5G4T-1 | Phase 3 | Papulopustular Rosacea | - | - |
5-FU Cream | Phase 3 | Actinic Keratosis (AK) | - | - |
Patidegib Topical Gel | Phase 3 | Gorlin Syndrome | - | - |
DER 45 EV | Phase 2 | Rosacea | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Sol-Gel Technologies Ltd.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Sol-Gel Technologies Ltd.'s (SLGL) pipeline across Phase 3, Phase 2. Its lead program is S6G5T-8 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sol-Gel Technologies Ltd.'s next FDA catalyst?→
Sol-Gel Technologies Ltd.'s (SLGL) next tracked catalyst is a Phase 3 expected August 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SLGL biotech catalysts?→
Add SLGL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sol-Gel Technologies Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.